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http://www.jeccr.com/content/32/1/17RESEARCH Open AccessSOX7 is down-regulated in lung cancer
Takahide Hayano1, Manoj Garg1*, Dong Yin2, Makoto Sudo1, Norihiko Kawamata2, Shuo Shi3, Wenwen Chien1,
Ling-wen Ding1, Geraldine Leong1, Seiichi Mori4, Dong Xie3, Patrick Tan1,5 and H Phillip Koeffler1,2,6Abstract
Background: SOX7 is a transcription factor belonging to the SOX family. Its role in lung cancer is unknown.
Methods: In this study, whole genomic copy number analysis was performed on a series of non-small cell lung
cancer (NSCLC) cell lines and samples from individuals with epidermal growth factor receptor (EGFR) mutations
using a SNP-Chip platform. SOX7 was measured in NSCLC samples and cell lines, and forced expressed in one of
these lines.
Results: A notable surprise was that the numerous copy number (CN) changes observed in samples of Asian,
non-smoking EGFR mutant NSCLC were nearly the same as those CN alterations seen in a large collection of NSCLC
from The Cancer Genome Atlas which is presumably composed of predominantly Caucasians who often smoked.
However, four regions had CN changes fairly unique to the Asian EGFR mutant group. We also examined CN
changes in NSCLC lines. The SOX7 gene was homozygously deleted in one (HCC2935) of 10 NSCLC cell lines and
heterozygously deleted in two other NSCLC lines. Expression of SOX7 was significantly downregulated in NSCLC
cell lines (8/10, 80%) and a large collection of NSCLC samples compared to matched normal lung (57/62, 92%,
p= 0.0006). Forced-expression of SOX7 in NSCLC cell lines markedly reduced their cell growth and enhanced their
apoptosis.
Conclusion: These data suggest that SOX7 is a novel tumor suppressor gene silenced in the majority of NSCLC
samples.
Keywords: CNAG, SNP-Chip, Lung cancer, SOX7, Promoter methylationIntroduction
Lung cancer is the leading cause of cancer-related
death in the world. If surgery is inadequate, further
therapy is rarely curative. Understanding the genomic
abnormalities in this disease affords the opportunity
to identify new therapeutic targets. An example is the
use of Gefitinib for patients whose non-small cell lung
cancer (NSCLC) has an epidermal growth factor
receptor (EGFR) mutation in either exon 19 or 21.
SOX7 is a member of the SOX (SRY-related high
mobility group box) transcription factors [1]. This
protein, together with SOX17 and SOX18, comprises
the SOX F subgroup [2] and helps mediate various
developmental processes including a role in the
regulation of hematopoiesis [3], cardiogenesis [4],
vasculogenesis [5,6], endoderm differentiation [7] and* Correspondence: csimg@nus.edu.sg
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reproduction in any medium, provided the ormyogenesis [8]. Recently, SOX7 has been proposed to
function as a tumor suppressor in colorectal and
prostate cancers [9,10]. We provide evidence that
SOX7 behaves as a tumor suppressor in lung tissue
and its expression is either low or silenced in the
majority of lung cancers.Materials and methods
Cell lines and tissue samples
Ten human lung cancer cell lines (H23, H460,
H820, H1299, H1975, HCC827, HCC2279, HCC2935,
HCC4006, PC14) were cultured in RPMI medium with
10% FBS and kept in a humidified atmosphere of
5% CO2. After IRB consent, total DNA and RNA of
normal and cancerous lung tissues were obtained
from the National University of Singapore (NUH-NUS
Tissue Repository). Also, sixty-two pairs of primary
NSCLCs and their corresponding adjacent normal
tissues, which were at least 5 cm away from thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Whole genome copy number analysis using high resolution SNP-Chips. (A, B) Heat map of DNA copy numbers found in the p
and q arms of the chromosomes (horizontal axis) of 56 NSCLC samples from the TCGA data base [top panel, Figure 1A], 9 NSCLC patient samples
with EGFR mutations [bottom panel, Figure 1A] and 8 NSCLC cell lines with EGFR mutations [Figure 1B] (vertical axis). DNA copy numbers are
indicated by colors (black, blue, green, pink, orange and red are 0, 1, 2, 3, 4 and ≥5 copies, respectively). Common copy number gain regions are
emphasized by red dotted rectangles. Common copy number loss region is emphasized by blue dotted rectangle. (C) At chromosome 8p23.1, a
homozygous deletion of SOX7 occurs in the HCC2935 NSCLC cell line. Red dots show raw data. Blue line denotes total gene dosage by CNAG;
level 2 indicates diploid (2N) amount of DNA. Sample is mostly hemizygous. Green small vertical bars immediately under the chromosome
display heterozygous SNP sites. The bottom lines (Red and Green) denote allele-specific gene dosage (one line indicates gene dosage of the
maternal allele, and the other indicates gene dosage of the paternal allele). Sample shows that chromosome 8 is hemizygously deleted except at
8p23.1 where the second allele is also lost in a small region resulting in homozygous deletion of the UNQ9391, RP1L1 and the SOX7 genes.
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Table 1 Common copy number genomic alterations in
NSCLC found in two cohorts: TCGA and EGFR mutant,
non-smoking Asians
Region of Chromosome Candidate target genes
Gain of 1q21.1q-24.2 Large fragment
Gain of 5p13.2 SKP2
Gain of 7p11.2 EGFR
Gain of 8q24.3 PTP4A3
Gain of 8q24.21 MYC, PVT1
Gain of 8q24.12 MTBP
Loss of 8p23.1 UNQ9391, RP1|1, SOX7
Gain of 11q13.2-13.3 CYCLIN D1, FGF3, FGF4, FGF19
Gain 12q14.2 TBK1, RASSF3
Gain 12q14.3 HMGA2
Gain of 12q13.3-14.1 CDK4
Gain of 12q12.1 KRAS
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Shanghai Chest Hospital (Shanghai, China), after their
written informed consent. None of the patients
received radio-chemotherapy prior to obtaining the
tissues. Lung cancer cells stably expressing either GFP
or SOX7 were generated by transducing them with
PLKO.1 lentiviral vector system (Sigma). Briefly, cells
were transduced with lentiviral vectors (SOX7 or
GFP) at an MOI of 25 with 5 ug/ml polybrene added
for 6 h. Twenty-four hours post-transduction, stable
cells were selected using 1ug/ml puromycin for
2-3 weeks.
High-density single nucleotide polymorphism-array analysis
Genomic DNA from NSCLC cells were subjected to
GeneChip Human mapping (1000 K array for the EGFR
mutant lung cancer samples and 250 K array for the
NSCLC cell lines). Both total and allelic-specific copy
numbers (CN) were determined using CNAG software
[11,12].
Quantitative real-time polymerase chain reaction
Real-time reverse transcriptase polymerase chain reaction
(RT-PCR) was performed using Maxima® First Strand
cDNA Synthesis Kit for RT-qPCR (Fermentas) according
to the manufacturer’s protocol. The expression level of
SOX7 mRNA in the samples was determined by quantita-
tive real-time PCR (7500 Fast Real-Time PCR System,
Applied Biosystems) using KAPA™ SYBR® FAST qPCR Kit
Master Mix (2X) Universal (Kapa Biosystems). Levels of
β-actin mRNA were used as an internal control. The delta
threshold value (DCt) was calculated from the given
threshold (Ct) value by the formula DCt = (Ct SOX7 – Ct
β-actin) for each sample.
Western blotting
NSCLC cells were lysed with ProteoJET™ Mammalian
Cell Lysis Reagent (Fermentas). Immunoblotting was
performed using either anti-SOX7 antibody (Sigma,
HPA009065) or anti-β-actin antibody (Sigma, AC-15)
and either secondary anti-Rabbit IgG antibody (GE
Healthcare, NA934) or anti-murine IgG antibody (GE
Healthcare, NA931), respectively. SOX7 or β-actin bands
were detected using Pierce® Fast Western Blot Kit,
SuperSignal® West Femto Substrate (Thermo SCIENTIFIC)
and SuperSignal® West Pico Chemiluminescent Substrate
(Thermo SCIENTIFIC), respectively.Gain of 12q11.21 DDX11
Gain 14q13.3 PAX9
Gain of 17q12 Her2
Gain of 17q25.3 TK1, BIRC5
Common genomic alterations found in both NSCLC samples with EGFR
mutations (9 samples) and those from the TCGA data base [56 samples,
probably these rarely have an EGFR mutation (Zhou et al. [14])].Bisulfite sequencing
Genomic DNA was modified by sodium bisulfite
using the CpGenome™ Turbo Bisulfite Modification Kit
(MILLIPORE). The following PCR primers were used
for bisulfite-modified genomic DNA [10]:Region (-687 to -440): 5’-TTAATTAGGTGGTTGAG
AATTAGAA and 5’-TAACCATAAACCCCTCAAAACA
Region (-71 to +251): 5’-TTTTGGAGAGTTATT
GGAGGA and 5’-CCTTAACCCAAACCATAAAAA
PCR products were cloned into either the pGEM-T or
pGEM-T easy vector (Promega), and at least four clones
from each sample were sequenced.
Methylation specific PCR (MSP) assay
Primers specific for the unmethylated (U) and methyl-
ated (M) sequences were designed by using Meth Primer
[13]. Primers sequences are as follows:
MSP-U (-683 to -493): 5'-TAGGTGGTTGAGAATT
AGAATGAT G and 5'-CTTTCAAAAATAACCAAACT
TCAAC
MSP-M (-683 to 493): 5'-TTAGGTGGTTGAGAATT
AGAACGAC and 5'-TCGAAAATAACCGAACTTCGA
MSP-U (+192 to +321): 5'-ATAAGGGTTTTGAGAG
TTGTATTTG and 5'-ACTCACCCAACATCTTACTA
AACTCA
MSP-M (+192 to +321): 5'-ATAAGGGTTTCGAGAG
TCGTATTC and 5'-TCACCCAACATCTTACTAAACT
CG
MTT assay
H23 and H1975 cells were seeded at 5 × 103 per well in
96-well plates. H1299 cells were seeded at 1.5 × 103 per
well in 96-well plates. MTT reagents were added to each
Table 2 Copy number genomic alterations that predominant in NSCLC from non-smoking Asians with mutant EGFR
compared to TCGA database
Region of Chromosome NSCLC with mutant EGFR (n=8) NSCLC from TCGA data base (n=56) Potential target gene(s)
Gain of 1p36.32-36.31 8/9(89) 15/56(27%) AJAP1
Gain of Ch2p Fewer alteration More alterations Large fragment
Gain of Ch3q Fewer alteration More alterations Large fragment
Loss of 6q22.3-27 Fewer alteration More alterations Large fragment
Loss of 9p21.3 1/9(11%) 19/56(34%) p14,p15,p16
Gain of 15q23-26.3 0/9(0%) 10/56(18%) Large fragment
Gain of 19q12 6/9(70%) 6/56(11%) Cyclin E1
Gain of 20q11.21 0/9(0%) 26/56(46%) BCL2L1, TPX2, MYLK2, DUSP15
Ratio of genomic alterations in NSCLC samples with EGFR mutations (9 samples) and 56 NSCLC samples from the TCGA data base. [Most samples from TCGA are
from Caucasians and thus we assume <7% will have EGFR mutation as previously noted (Zhou et al. [14])].
Figure 2 Down-regulation of SOX7 in NSCLC cells. (A) Real-time
reverse transcription-PCR measurement of expression of SOX7 mRNA
in 10 NSCLC cell lines and 5 normal lung samples. Relative
expression level 1.0 represents the mean expression of the 5 normal
lung tissues. (B) Western blot analysis of SOX7 expression of the
same 10 NSCLC cell lines. β-actin is used as the loading control.
(*) denotes EGFR mutated cell lines.
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manufacturer’s instructions (Promega).
Cell cycle analysis by flow cytometry
2x106 cells stably expressing either SOX7 or GFP
were seeded into 6-well plates for 24 h. Cells were
harvested and washed twice with cold phosphate-
buffered saline (PBS) and fixed in 75% ethanol
(precooled at -20°C) for 24 h at 4°C. The fixed cells
were washed twice with 2 ml of cold PBS. Cells then
were stained with 500 ul of propidium iodide (PI)
staining solution (50 ug/ml PI, 0.1%Triton X-100, 200
mg/ml DNase-free RNase in PBS) for 30 min at room
temperature in the dark. Ten thousand events per
sample were acquired using a LSR-II flow cytometer
(Becton-Dickinson, San Jose, CA, USA), and the
percentage of cells in G0/G1, S, G2/M and Sub-G2/M
phases of the cell cycle were determined using FACS
DIVA software (Becton-Dickinson).
Annexin V and propidium iodide (Annexin V–PI) staining
apoptosis test
4 × 105 cells were seeded into each well of a 6-well plate
for 48 h. The staining was carried out according to the
instructions provided by the manufacturer of PE
Annexin V Apoptosis Detection Kit I, BD Pharmingen
(BD Biosciences, USA). Briefly, cells were washed with
PBS, suspended in 1X binding buffer and then added
with annexin-V APC and propidium iodide (PI) for
15 min. The samples were then analyzed by LSR-II flow
cytometer (Becton-Dickinson, San Jose, CA, USA).
Results
Whole genomic copy number analysis using high
resolution SNP-Chips in NSCLC samples and cell lines
Initially, genomic alterations were examined in a
small sample set of Asians with NSCLC with EGFR
mutations. Nine clinical NSCLC samples with EGFR
mutation were analyzed for copy number aberrations(CNA) using a high-resolution SNP-Chip microarray
platform (Affymetrix). The alterations of the CNA in
these mutant EGFR samples were compared to 56
NSCLC samples from The Cancer Genome Atlas
(TCGA) data base. The mutational status of EGFR in
these 56 NSCLC samples is not available; but because
most of the patients are Caucasians from the USA,
Figure 3 Downregulated SOX7 in NSCLC compared to matched normal lung samples. (A) Waterfall graph showing SOX7 mRNA expression
in 62 paired human NSCLCs compared to normal lung tissue from the same patient. SOX7 mRNA expression was normalized to β-actin mRNA.
(B) Statistical analysis of SOX7 mRNA expression in 62 paired human NSCLCs and normal lung tissues. Delta threshold cycle value (DCt) was calculated
from the given threshold (Ct) value by the formula DCt = (Ct SOX7 – Ct β-actin) in each sample. P value was calculated with Paired T-test.
(C) Relationship between significant SOX7 mRNA levels in the NSCLC samples and clinicopathological features of the patients and their NSCLC.
Statistical differences were observed in histological differences (p=0.0222). The p values were calculated with Mann–Whitney T-test.
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than 7% of these cases [14]. The overall genomic pro-
files of NSCLC were highly similar when comparing
our samples having a mutant EGFR and the samples
in the TCGA data base (Figure 1A; Table 1). This is
consistent with our earlier study where we reported
this observation across a larger cohort [15]. For ex-
ample, 78% (7/9) and 75% (42/56) of samples of both
cohorts had gain at 5p13.2, and 67% (6/9) and 73%(41/56) of samples had gain at 8q24.12-24.3, respect-
ively. Nevertheless, several CNAs were associated with
the EGFR mutation-positive NSCLC samples (Table 2).
For example, 89% (8/9) of our EGFR mutant tumors
versus 27% (15/56) of the TCGA samples had CN
gain at 1p36.31-36.32; also, 56% (5/9) of our EGFR
mutant samples versus 11% (6/56) of the TCGA sam-
ples had gain at 19q12. Clearly, too few EGFR mutant
samples were analyzed to perform statistical analysis.
Figure 4 (See legend on next page.)
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Figure 4 Methylation analysis of upstream regions of SOX7 gene. (A) Schematic illustration of CpG sites spanning 1,500 bp upstream and 350 bp
downstream of the transcription start site of SOX7 transcription. Black arrow denotes the transcription start site (+1). Vertical pink bars denotes the CpG
sites. Arrowed bars define the regions subjected to bisulfite sequencing (BS). Bars with circles at their end define the regions subjected to methylation
specific PCR (MSP). (B) Bisulfite sequencing of SOX7 gene in NSCLC cell lines. Each circle in each horizontal row represent the analysis of a single clone of
bisulfite-treated DNA encompassing either 20 or 35 CpG sites (-678 to -440, left panels; -71 to +251, right panels, respectively). Open and solid circles
represent unmethylated and methylated CpG sites, respectively. (C) MPS analysis of upstream region of SOX7 gene in NSCLC cell lines. PCR products in
lanes marked “U” and “M” are obtained with unmethylated-specific and methylated-specific primers, respectively. (D) Bisulfite sequencing of SOX7 gene in
NSCLC samples and their matched normal lung tissues as described for the NSCLC cell lines in Figure 4B.
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cell lines. These cell lines frequently had CN gain
throughout much of each chromosome (Figure 1B).
Loss of CN in the NSCLC samples and cell lines was
infrequent, occurring slightly more often at 6q22.3-27,
8p, and 9p21.3 (Figure 1A, B; Tables 1, 2).
Cell lines enhance the opportunity to discover homo-
zygous deletions because they are not contaminated with
normal cells. A homozygous deletion often marks the
position of a tumor suppressor gene that may be dele-
terious for either development or progression of cancer.
A small homozygous deletion at 8p23.1 was found in
one (HCC2935) of 10 NSCLC cell lines. The SOX7 was
located in this small homologously deleted region
together with 2 other genes (UNQ9391 and RP1L1)
(Figure 1C; Table 1).Expression of SOX7 in NSCLC
Expression of SOX7 gene was examined initially in
10 human NSCLC cell lines using quantitative RT-PCR
(qRT-PCR). Compared with the average SOX7 mRNA
level (arbitrary level 1) of five normal lung tissues, nine
of the 10 cell lines exhibited extremely low levels of
SOX7 mRNA (mean level was 12% of the average found
in the normal lung tissues) (Figure 2A). In addition,
SOX7 protein expression was only weakly detected inTable 3 Summary of methylation analysis of SOX7
Cell Lines SOX7 Western BS (-687 and -493) MSP (
H23 - (98%)
H460 +/- (92%)
H820 - (70%)
H1299 - (85%)
H1975 - (99%)
HCC827 - (80%)
HCC2279 - (75%)
HCC2935 - Deleted
HCC4006 - N.D.
PC14 ++ N.D.
-, +/-, ++: no, slight, moderate SOX7 protein expression.
BS, Bisulfite sequencing; MSP, Methylation specific PCR; U, Unmethylated; M, Methyltwo (H460 and PC14) of these 10 NSCLC cell lines
(Figure 2B).
Next, a large number of clinical NSCLC samples
were examined for expression levels of SOX7 mRNA in
62 pairs of tumors and their matched normal lung tissues
using qRT-PCR (Figure 3A). Paired T-test analysis showed
that the expression of SOX7 mRNA was significantly
decreased in fifty-seven of 62 (92%) NSCLC samples
compared with adjacent normal lung tissues (p= 0.0006)
(Figure 3B). The correlation between SOX7 mRNA levels,
and clinical as well as pathologic characteristics was
analyzed (Figure 3C). Expression levels of SOX7 mRNA
were correlated with histology (adenocarcinoma had lower
expression than either squamous or adenosquamous
carcinoma, p= 0.0222) and tumor differentiation (poorly
differentiated had lowest expression, p= 0.0607). In con-
trast, no significant correlations were identified between
SOX7 expression in the NSCLC and age, gender, smoking
history, tumor stage and invasion (Figure 3C).
Upstream region of SOX7 gene in lung cancer cell lines
was highly methylated
The mechanism underlying the down-regulation of SOX7
expression in lung cancer was explored. The upstream
region of SOX7 gene has several dense CpG islands (Fig-
ure 4A). Primers for Bisulfite Sequencing and Methylation
Specific PCR (MSP) assays were designed (Figure 4A).-683 and -493) BS (-71 to +251) MSP (+192 and +321)
M (<1%) U
M (0%) U
M (<1%) U
M (8%) U, M
M (99%) U, M
M (3%) U, M
M (75%) U, M
Deleted Deleted Deleted
U, M (0%) N.D.
M (<%) N.D.
ated; N.D., Not done.
Figure 5 Forced-expression of SOX7 slows NSCLC proliferation. NSCLC cell lines (H23, H1299 and H1975) were stably infected and selected
for stable expression of SOX7. (A) SOX7 vector uninfected (WT), GFP expression vector infected (GFP) or SOX7 expression vector infected SOX7
cells were confirmed in the three NSCLC cell lines by western blotting. β-actin was the control for equal loading. (B) Proliferation was measured
by MTT assay. Each cell line was seeded in 96 well plates and absorbance was measured after 1, 2, 3 and 4 days culture. Results show the
mean ±SD of quintuple wells. ** or ***, signifies statistical differences p < 0.01 or p < 0.001, respectively.
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CpG rich region (-687 to -440) was hypermethylated in all
7 of the examined NSCLC cell lines. The downstream re-
gion (-71 to +251) was hypermethylated in two (H1975
and HCC2279) of 9 NSCLC cell lines (Figure 4B). MSP
analysis confirmed the Bisulfite Sequencing technique,
showing that the upstream region (-683 to -493) was
highly methylated in eight (H23, H460, H820, H1299,
H1975, HCC827, HCC2279, PC14) of the 9 NSCLC cell
lines (Figure 4C and Table 3). As expected, we could not
amplify either the upstream or downstream regions of the
SOX7 gene in the HCC2935 cells consistent with a homo-
zygous deletion of the gene in these cells (data not shown).
A perfect correlation between upstream methylation and
SOX7 expression did not occur. HCC4006 had only mod-
est positivity by MSP but did not express SOX7; and PC14
was methylated by MSP examination, but expressed
SOX7. Also in contrast to the cell line data, the Bisulfite
Sequencing analysis showed that the upstream region
(-687 to -440) was hypermethylated in one of 5 lung
tumor samples. We did not have RNA or protein available
for these samples to examine SOX7 expression. The
downstream region (-71 to +251) was neither methylated
in NSCLC nor matched normal samples (Figure 4D),which was consistent with the methylation pattern noted
in the NSCLC cell lines.Forced-expression of SOX7 in NSCLC cells slowed their
proliferation
We developed stable clones of three NSCLC cell lines
(H23, H1299, H1975) expressing a SOX7 expression
vector (Figure 5A). These NSCLC cells had statistically
significantly slower growth than the vector control cells
(H23 and H1975, p= < 0.001 and H1299, P=<0.01,
respectively) (Figure 5B).Effect of SOX7 expression on cell cycle regulation
To study the effect of SOX7 expression on the cell cycle,
we used H23 and H1299 human lung cancer cell lines
stably expressing either SOX7 or GFP (used as control).
Fluorescence-activated cell sorting (FACS) analysis for
the cell cycle showed that forced expression of SOX7 in
H23 and H1299 cell lines resulted in an accumulation
of a sub-G1 peak compared to the control cells. The
percentage increase in the sub-G1 phase was from 3%
(control) to 7% (SOX7) for H23 cells and 5% (control) to
11% (SOX7) for H1299 cells. The proportions of cells in
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unchanged in experimental versus control cells. These
results demonstrate that SOX7 forced expression in lung
cancer cell lines was associated with a sub-G1 popula-
tion which probably reflected apoptosis (Figure 6).
Forced expression of SOX7 induces apoptosis in H23 and
H1299 cell lines
To explore further whether forced expression of SOX7
resulted in apoptotic cell death, Annexin V-APC/
propidium iodide (PI) staining was performed for
H23 and H1299 human lung cancer cell lines stably
expressing either SOX7 or GFP (used as control).
Based on Annexin V and PI staining, SOX7 expression
led to increased early (AV+PI-), as well as, late (AV+PI+)
apoptotic cells. A notable 21% and 33% of the H23
SOX7 cells were early and late apoptotic cells, respectively.
In comparison, 3% and 5% of the H23 GFP cells (control
cells) were early and late apoptotic cells, respectively.
Less dramatically, 4% and 6% of early and late apoptotic
H1299 SOX7 cells, respectively compared to 0.5% and
4% of early and late apoptotic H1299 GFP cells (control),
respectively (Figure 7).Figure 6 Forced-expression of SOX7 increases subG1 phase of cell cy
H1299) in sub-G1, G0/G1, S and G2/M phases as determined by flow cytometry
subG1 phase of cell cycle in H23 and H1299 compared to GFP (control) cell. TDiscussion
We initially performed CN analysis of 9 NSCLC
samples and 8 NSCLC cell lines, each with an EGFR
mutation. Their pattern of genome alterations were
compared to the SNP-Chip copy number changes
found in 56 NSCLC in the TCGA data base. Our
samples were from non-smoking Asians who had
EGFR mutations. The TCGA samples were composed
of predominantly Caucasians who smoked and there-
fore less than 7% of samples would be expected to
contain an EGFR mutation [14]. Remarkably, their
genomic landscape of copy number change was very
similar. All the samples had increase in CN through-
out the genome (predominantly 3N), especially at 1q,
5p, 7p, 8q, 11q, 12q, 14q, 17q. However, although
sample numbers were small, eight genome regions had
notable difference in copy number changes between
the NSCLC samples with EGFR mutation compared to
those in the TCGA data base samples (Table 2) in-
cluding 1p36.31-36.32 [8/9 (89%) versus 15/56 (27%)]
and 19q21.3, [5/9 (56%) versus 6/56 (11%)], respect-
ively. Further studies are required to clarify what the
target genes are in these regions (Table 1).cle in NSCLC. Histogram represents the distributions of cells (H23 and
. Forced expression of SOX7 resulted in increased percentage of cells in
he figure is the representative of three independent experiments.
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gous mutation at 8p23.1 which encompassed the SOX7
gene (Figure 1). Interestingly, 8p is one of the few regions
in the NSCLC samples associated with deletions. Homo-
zygous deletion usually represents the loss of a tumor sup-
pressor gene deleted by the tumor. Our further studies
focused on SOX7. Expression levels of SOX7 mRNA and
protein were diminished in eight of 10 NSCLC cell lines
(Figure 2), as well as in fifty-seven of 62 (92%) NSCLC pa-
tient samples compared with their matched normal tis-
sues. Expression level of SOX7 in NSCLC samples was
correlated with their histology, with levels being lower in
adenocarcinomas compared with adenosquamous and
squamous carcinomas (Figure 3). Furthermore, force-
expression of SOX7 in several NSCLC lines (H23, H1299,
and H1975) having constitutively low level of SOX7,
suppressed their cellular proliferation and enhanced their
apoptosis (tested with H23and H1299) (Figure 5, 6 and 7).
Recent studies of SOX7 in colorectal and prostate can-
cers showed that levels of this transcription factor were low
in these cancers in part due to aberrant DNA methylationFigure 7 Forced-expression of SOX7 increases apoptosis in NSCLC by
V-FITC staining in X-axis and propidium iodide in Y-axis. Dual staining of cells w
into four regions. Region Q1 shows the necrotic cells, Q2 shows the late apopto
Forced expression of SOX7 resulted in increase of early and late apoptotic cells
representative of three independent experiments.of the gene, and the protein behaved as a tumor suppressor
gene in these cancers [10,15]. We found that the upstream
region (-687 to -440) of SOX7 was highly methylated in
eight of 10 NSCLC cell lines (Table 3). Paradoxically, ex-
pression of SOX7 and methylation as measured by MSP
analysis were not correlated in the H460 and PC14 cells,
and only one of 5 fresh NSCLC samples was highly methyl-
ated in the promoter region of SOX7. This suggests that
additional epigenetic changes are required for silencing of
this gene in a proportion of NSCLC.
In summary, our study suggests that SOX7 is a
tumor suppressor in the lung. One or occasionally
both alleles are lost in the lung cancer. Other times
the upstream CpG island of the SOX7 gene is robustly
methylated, associated with low expression of the
gene. SOX7 levels were nearly undetectable in seven
of 9 (78%) highly methylated NSCLC cell lines, and
levels were low in 57 of 62 (92%) NSCLC samples
compared to adjacent normal tissues. Loss of SOX7
expression appears to provide a growth advantage to
NSCLC cells.Annexin V-PI staining. Flow cytometry profile represents Annexin
ith Annexin V-APC and propidium iodide enabled categorization of cells
tic cells, Q3 shows the live cells and Q4 shows the early apoptotic cells.
in H23 and H1299 compared to GFP (control) cell. The figure is the
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